EME and AprilBio begin joint development of next-generation VHH antibody drug discovery.
Epsilon Molecular Engineering Co., Ltd. (Head office: Saitama City, Saitama Prefecture; President and CEO: Naoto Nemoto; hereinafter referred to as "the Company")AprilBio Co., Ltd. AprilBio (397030.KQ), a South Korean company, has entered into a strategic partnership and commenced joint development of next-generation VHH antibody drugs. The two companies recently signed a Memorandum of Understanding (MOU) for the purpose of joint research and development and global commercialization, and have agreed to leverage their respective core platform technologies.
Press releaseCLICK HERE.
This agreement represents a crucial step in expanding our antibody technology platform to the global market. Through this partnership, we aim to demonstrate the innovativeness of our technology, accelerate the development of new therapeutic drugs, and expand the therapeutic application of next-generation antibodies beyond Japan.
[Contact]
Epsilon Molecular Engineering Co., Ltd.
Business Development Department
Email: biz_dev@epsilon-mol.co.jp